Market Analysis - Biomarkers 2017
The global biomarkers market is expected to reach $45.55 Billion by 2020 from $24.10 Billion in 2015, at a CAGR of 13.58% between 2015 and 2020. Increasing healthcare expenditure & R&D spending and the increasing utility of biomarkers for diagnostics are expected to drive the market. Market growth will also be aided by the low cost of clinical trials in developing countries and new initiatives undertaken for biomarker research. On the other hand, the need for high capital investment, low benefit-cost ratio, poorly suited regulatory & reimbursement systems, and the high cost of tests and sample collection & storage are the major factors restraining the growth of this market.
The applications included in this report are diagnostics development, drug discovery & development, personalized medicine, disease risk assessment and other applications. The disease indication segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.
Major players in this market include QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), Bio-Rad Laboratories (U.S.), Enzo Biochem (U.S.), EKF Diagnostics Holdings plc (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.).
Diagnostic biomarkers are divided in two major types which include biomarkers of exposure and biomarker of disease. Biomarkers of exposure are an emerging technology of identifying the hazardous chemical level in individual body. These biomarkers enable the diagnosis of abnormal activities to calculate the pre-disease condition. Biomarkers of disease are used in identification of disease condition and also help in validation of clinical trials for novel drug.
Biomarkers market revenues share by segment, 2012 and 2020
Diagnostic biomarker market is growing with development of technologies in clinical laboratory tests, imaging exams, and in recent years biomarker tests are impacting the clinical management of patients. Biomarkers are identified conventionally by analyzing the science of pathophysiology and epidemiology, which derive insensitive and nonspecific markers. Diagnostic biomarker technology is expected to transform the scenario of clinical research, medical practice and drug development, as technological advances are changing from conventional approach of pathophysiology/epidemiology to biomarker studies such as genomics and proteomic. The amount of information provided by the biomarker helps in pharmaceutical drug development, diagnosis of critical diseases, and in clinical trial of drugs. The diagnostic biomarker technology provides simple diagnostic treatments to pathologists to perform faster, accurate disease identification, which enables physician to prescribe better treatments for those diseases.
Though as on today there are immense developments in infrastructure for data sharing and analysis such as bioinformatics, the utility is not to its best. Furthermore, there is no standard regulatory framework globally. For example, countries in the European Union and other regions have their own set of regulations, which may be a bigger challenge in conducting transnational research and data sharing. However, the role of biomarkers is increasing with its crucial application in diagnosis of fatal diseases such as cancer and cardiovascular diseases. Biomarkers in these cases enable early diagnosis and are of immense importance in designing effective treatments and progress. Reimbursement issues are being solved with the intervention of regulatory authorities, which is expected to propel the growth of the market for diagnosis at commercial level.
Asia Pacific Market Review:
Heart diseases are the leading cause of death in worldwide and Asia Pacific has the significant share especially in coronary heart disease. Diagnosis for cardiovascular disease is done through conventional methods such as clinical observation, electrocardiogram (ECG) findings. According to data published by ministry of health in China, about 203 million people are suffering from cardiovascular diseases and this number is expected to increase by 73% in 2030. Projected trends in blood pressure, increased cholesterol and active smoking are also increase the number of CVD by an additional 23% which denotes 21.3 million cardiovascular events. Demographic changes such as aging population and lesser younger people is the main driver for increased CVD disease. Biomarker market is expected to increase its presence as biopharmaceutical companies are investing more in Asian countries for drug discovery and development since market for health care process is more in Asia Pacific region. Application of biomarkers in drug discovery and development process, personalized medicine, molecular diagnosis, and diagnosis of other diseases are increases the interest of research based pharmaceutical company to develop novel biomarkers.
KEY BENEFITS OF THE REPORT
- The report offers an assessment and ranking of the factors that favor the biomarkers market growth and those factors which act as a hindrance for the growth of the market
- Forecast period for estimating market size is from 2013 to 2020. Two historic years include 2011 and 2012
- The report identifies top investment pockets and offers an analysis of top winning strategies for diagnostic biomarker industry.
- The report analyses the various strategies adopted by some of the key companies in the industry.
- The report tracks and analyses key innovations and patents for biomarkers in the last five years
BIOMARKERS MARKET KEY SEGMENTS
Diagnostic Biomarkers Market is segmented as follows:
Global Biomarkers Market, by Type
- Safety Biomarkers
- Efficacy Biomarkers
- Pharmacodynamics Biomarkers
- Predictive Biomarkers
- Prognostic Biomarkers
- Surrogate Biomarkers
- Validation Biomarkers
Global Biomarkers Market, by Application
- Diagnostics Development
- Drug Discovery & Development
- Personalized Medicine
- Disease Risk Assessment
- Other Applications
Global Biomarkers Market, by Disease Indications
- Cardiovascular Disorders
- Neurological Disorders
- Immunological Disorders
- Other Diseases
Global Biomarkers Market, by Region
- North America
- Rest of the World
The geographic analysis reveals that North America will account for the largest share of the global biomarkers market in 2015. Growth in this market can be attributed to strong growth trends in pharmaceutical companies and CROs. The Asian regional segment is expected to register double-digit growth from 2015 to 2020 owing to the expansion of leading biomarker companies and increased R&D spending. R&D spending in Asia increased from $177 billion in 2003 to $329 billion in 2010, at a CAGR of 9.29%. The R&D spending in Asia accounted for 27.13% of the global R&D expenditure in 2010.
The Omics technology segment holds the largest share of ~75% of the biomarker discovery market, primarily due to the increase in adoption of proteomics and genomics technologies, globally.
The emerging Asia-Pacific region exhibits high growth opportunities for industry participants. Growing economies such as China and India are experiencing an increasing rate of biomarkers research activities. This is attributed to the rising number of contract research organizations and the low cost of conducting clinical trials in Asia-Pacific nations when compared to developed countries.
Importance & Scope:
For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.
The biomarkers market presents the largest of all opportunities in representative disease subsegments. This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil and Russia.
This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.
Scope of Report
Current and projected product forecasts during the forecast period (2013 to 2018) are discussed. In addition, new products approved in 2012 and 2013 by the FDA, and those products expected to be approved within the forecast period, are projected. Figures are estimated for 2013, except where actual results have been reported, due to the timing of the release of the report. For all areas, including very large markets segments such as infectious disease and cardiovascular, specific mechanisms of action are discussed in detail. Market figures include the bundled value of the drug and the biomarker as it is impossible to quantitate the composite values of each.
The report includes an analysis of leading and emerging competitors in the current worldwide biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies.
Why Baltimore, USA?
In a study conducted to evaluate a change in symptoms and radiographic features in patient with the help of Biomarkers, they identified that the research related to biomarkers was oftenly conducted in Baltimore, USA. There are more than 200 research firms in Baltimore.
There are several self-sustaining, not-for-profit, research support organization focused on facilitating the identification, quantification and validation of biomarkers for use in diagnosis, prognosis and treatment of diseases in Baltimore.
Tracks 1: Biomarkers
Track 2: Cancer Biomarkers
Track 3: Molecular Biomarkers
Track 4: Types of Biomarkers
Track 5: Biomarkers in Clinical Research & Development
Track 6: Biomarkers in Drug Discovery
Track 7: Biomarkers in Pathology
Track 8: Biomarkers for Disorders
Track 9: Oncologists: Biomarkers
Track 10: Personalized Medicine and Data Analysis
Track 11: Cancer Research
Track 12: Clinical Trials
Track 13: Translational Biomarkers & Diagnostics
Track 14: Biomarkers & its Diseases
Track 15: Functional Genomics and Cytogenetic Biomarkers
Track 16: Omics Technologies in Biomarkers Discovery and Validation
Track 17: Techniques to Maximize Biomarker Identification
Track 18: Biomarkers and Pharmacology
Track 19: Case Reports
Track 20: Biomarkers: Entrepreneur Investments Meet
Why to attend Biomarkers?
Team Biomarkers aims to deliver a perfect platform to the scientific and industry personnel to share their knowledge and expertise. It gives opportunity to conduct demonstrations, distribute information, meet with current and potential speakers/Delegates all around the world which are working on the very emerging field of Biomarkers, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Biomarkers and Clinical Research fields are hallmarks of this conference.
A Unique Opportunity for Advertisers and Sponsors at this International event: http://biomarkers.conferenceseries.com/sponsors.php
Major associations and media partners around the globe:
- Biomarkers Profile corporation
- International society for oncology and Biomarkers
- The Biomarkers consortium
- World molecular imaging society
- Society of nuclear medicine and molecular imaging
- European society of molecular imaging
- Biomarkers Society
- Genetic engineering and Biotech News
- Insight Pharma
- Bio IT World
Major associations and media partners around USA:
- Alliance for commercialization of Canadian Technologies
- University Health Networks
- Ontario Cancer Biomarker Network
- National Research council
- Canadian association of Neuroscience
- Clinical Research association of Canada
- Hypertension Canada
- Biotechnology Canada
For Biomarkers mainly the target audiences are Universities, Research institutes, Hospitals, Industries, Medical device manufacturing companies, CROs and Associations.
Top Universities in USA:
- The Johns Hopkins University
- Massachusetts Institute of Technology
- University of Maryland
- University of Pennsylvania
- University of Illinois
- Harvard University
- Duke University
- California Institute of Technology
- Stanford University
- Princeton University
Glance at market of Biomarkers and Clinical Research:
Total market value of Biomarkers in 2014 is $5.95 Billion and it is expected to reach $30 Billion in 2020 growing at CAGR of 16% from 2014 to 2020. Biomarkers major verticals are usually supplied by market of application and market of services. Common Annual Growth Rate of more than 37% is gained by market for application and Common Annual Growth Rate of more than 39% are gained from the market of services. Thus the common annual growth is 49% by revenue. Nowadays scope of biomarkers has a vital role in efficacy of the therapeutic process all around the world. Establishing the standardization of drug development has a major role for the development of disease pathway. Also, Research portfolio of biomarkers discovery has an application in all the major scientific studies.
Conference Series LLC cordially invites all the participants across the globe to attend the “10th International Conference on Biomarkers & Clinical Research” during October 18-20, 2017 at Baltimore, USA.
Biomarker congress will enable to put forth the holistic scientific approach to validate the existing and development of novel biomarkers as to better understanding of diseases and diagnosis. The past six conference series of biomarkers meeting have grounded the best possible researchers in the field of biomarkers from diverse scientific disciplines, and so will be the upcoming.
Biomarkers are important for streamlining drug discovery and development. In addition, biomarkers can be widely used as a tool for disease diagnosis, personalized medication in clinical research. Study design and statistical analysis for biomarker research incorporates various tools from bioinformatics. It further involves patient segmentation and stratification by successful integration of diagnostic tools and clinical data annotation inclusive of classification distribution metrics and pattern recognition. The global market for biomarkers in data statistics is estimated at about $2.4 billion in 2011 and further projected to reach $7.6 billion by 2017 registering a CAGR of 18.3% during the period 2007-2017. The organizations involved are Affymetrix, Agilent Technologies, Biomax Informatics, Illumina, Qiagen etc amongst others across the globe.
Conference Series LLC organizes 3000+ Global events in conference series every year across the globe with support from 1000+ more scientific societies and Publishes 700 Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board members.
Why to attend???
With individuals from around the globe concentrated on finding out about Biomarkers and Clinical Research; this is your best chance to achieve the biggest gathering of members from the Biomarkers and Clinical Research people group. Direct presentations, circulate data, meet with present and potential researchers, make a sprinkle with cutting edge medicines, and get name acknowledgment at this 3-day occasion. Widely acclaimed speakers, the latest procedures, advancements, and the most current upgrades in Biomarkers and Clinical Research are the signs of this gathering.
- Biomarkers and Clinical Research Scientists, Students
- Biomarkers and Clinical Researchers
- Medical Colleges
- Biomarkers and Clinical Research Associations and Societies
- Business Entrepreneurs
- Software developing companies
- Manufacturing Medical Devices Companies
- Cancer Researchers
- Data Management Companies
- Pharmaceutical Companies
- Diagnostics Companies